57
In June, the US Food and Drug Administration (FDA) suspended new clinical trials that export the cells of US participants to “hostile” countries’ laboratories for genetic engineering (1). The decision came just after the National Institutes of Health blocked researchers from designated “countries of concern” from its controlled access data repositories (2). Protecting consent and genomic data is imperative, but embedding geopolitical boundaries into research oversight fractures the collaborative foundation of modern biomedicine and delays global therapeutic innovation.